Studies have shown that the internal components of the TME can change and that its status is transmitted by signaling pathways that influence the efficacy of antineoplastic drugs such as programmed cell death-1 (PD-1) inhibitors in STS.[25] In addition, recent studies indicate that remodeling of the TME by immune checkpoint inhibitors or adoptive cell transfer exhibited satisfactory effects in reducing tumor progression and improving treatment outcomes in some types of STS.[26,27] This evidence suggests that remodeling of the TME in STS is of clinical significance and deserves further study. This evidence concerns the gene PDCD1 and telomere syndrome.